LCM
NVCR icon

Laurion Capital Management’s NovoCure NVCR Stock Holding History

Laurion Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-220,000
Closed -$13.9M – 1199
2019
Q2 		$13.9M Buy
+220,000
New +$11.1M 0.14% 157

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Laurion Capital Management's NVCR Position: Q3 2020 in Review

Laurion Capital Management sold out of NovoCure (NVCR) in Q3 2020, closing a stake of 21,975 shares — an estimated $1.3M sold.

Laurion Capital Management first reported a position in NVCR in Q3 2017 and held it in 3 quarters. The position peaked at $11.1M in Q3 2017. 282 funds tracked by Wall St. Rank hold NVCR as of Q3 2020.

  • Laurion Capital Management reported no remaining NovoCure position as of Q3 2020 after selling out during the quarter.
  • Laurion Capital Management sold 21,975 NovoCure shares in Q3 2020, an estimated $1.3M.
  • Laurion Capital Management first reported a position in NovoCure in Q3 2017 and held it in 3 quarters.
  • Laurion Capital Management's NovoCure position peaked at $11.1M in Q3 2017.
  • 282 funds tracked by Wall St. Rank held NovoCure as of Q3 2020.

Based on Laurion Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.